SCHEMBL189559

SCHEMBL189559

OCc1cc(-c2ccc(OCc3ccccc3)cc2)no1

nearest known ligand 0.66

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.66
RAB9A P51151 4/20 0.63
L3MBTL1 Q9Y468 4/20 0.63
NPC1 O15118 3/20 0.63
SMN1; SMN2 Q16637 3/20 0.63
TDP1 Q9NUW8 3/20 0.63
MAPT P10636 3/20 0.62
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
SMPD1 P17405 1/20 0.56
POLB P06746 1/20 0.54
GSTP1 P09211 1/20 0.51
PTGS1 P23219 1/20 0.51
PTGS2 P35354 1/20 0.51
MCL1 Q07820 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL190469 0.86 NOTUM (0.66) NOTUMRAB9AL3MBTL1NPC1SMN1; SMN2
SCHEMBL190599 0.86 RAB9A (0.64) RAB9AL3MBTL1NPC1SMN1; SMN2TDP1
SCHEMBL190361 0.84 RAB9A (0.54) NOTUMRAB9AL3MBTL1NPC1SMN1; SMN2
SCHEMBL189513 0.83 RAB9A (0.53) NOTUMRAB9AL3MBTL1NPC1SMN1; SMN2
SCHEMBL190343 0.83 RAB9A (0.62) RAB9AL3MBTL1NPC1SMN1; SMN2TDP1
SCHEMBL14707191 0.83 RAB9A (0.61) RAB9AL3MBTL1NPC1SMN1; SMN2TDP1
SCHEMBL189840 0.83 RAB9A (0.59) RAB9AL3MBTL1NPC1SMN1; SMN2TDP1
SCHEMBL189312 0.81 RAB9A (0.54) NOTUMRAB9AL3MBTL1NPC1SMN1; SMN2
SCHEMBL189684 0.81 RAB9A (0.54) NOTUMRAB9AL3MBTL1NPC1SMN1; SMN2
SCHEMBL189501 0.81 RAB9A (0.59) RAB9AL3MBTL1NPC1SMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2917188-B1 SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2018-08-01 EP disclosed
US-9724335-B2 Solid dispersions of insoluble drug and preparation method thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2017-08-08 US disclosed
US-20170105973-A1 SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF SK BIOPHARMACEUTICALS CO., LTD. 2017-04-20 US disclosed
US-9566268-B2 Solid dispersions of insoluble drug and preparation method thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2017-02-14 US disclosed
US-20160346258-A1 SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF SK BIOPHARMACEUTICALS CO., LTD. 2016-12-01 US disclosed
US-9439970-B2 Solid dispersions of insoluble drug and preparation method thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-09-13 US disclosed
US-9290464-B2 Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-03-22 US disclosed
EP-2401263-B1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO LTD (KR) 2016-02-17 EP disclosed
US-20150283243-A1 SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF SK BIOPHARMACEUTICALS CO., LTD. a corporation 2015-10-08 US disclosed
EP-2917188-A1 SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF SK Biopharmaceuticals Co., LTD (KR) 2015-09-16 EP disclosed
US-8828992-B2 Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating Parkinson's disease using the same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-09-09 US disclosed
WO-2014073889-A1 SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-05-15 WO disclosed
EP-2566475-A2 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION SK Biopharmaceuticals Co., Ltd. (KR) 2013-03-13 EP disclosed
US-20130046001-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION SK BIOPHARMACEUTICALS CO., LTD. (KR) 2013-02-21 US disclosed
EP-2401263-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK Biopharmaceuticals Co., Ltd. (KR) 2012-01-04 EP disclosed
US-20110301150-A1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO., LTD. 2011-12-08 US disclosed
WO-2011139079-A2 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION SK BIOPHARMACEUTICALS CO., LTD. (KR) 2011-11-10 WO disclosed
WO-2010098600-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK HOLDINGS CO., LTD. (KR) 2010-09-02 WO disclosed
US-20080045580-A1 Novel Isoxazole Compounds Having Ppar Agonist Activity DR REDDY'S LABORATORIES LIMITED (IN) 2008-02-21 US disclosed
WO-2006042245-A1 NOVEL ISOXAZOLE COMPOUNDS HAVING PPAR AGONIST ACTIVITY DR. REDDY'S LABORATORIES LTD. (IN) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160346258-A1 SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF SI, CYP3A7, ABCG2 NOTUM 828/4885RAB9A 1475/4885L3MBTL1 4553/4885
US-20110301150-A1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME MAOB, MAOA, PARK7 NOTUM 1260/4885RAB9A 1245/4885L3MBTL1 4729/4885
US-20080045580-A1 Novel Isoxazole Compounds Having Ppar Agonist Activity PPARG, PPARA, PPARD NOTUM 1325/4885RAB9A 2782/4885L3MBTL1 4836/4885
US-20170105973-A1 SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF SI, CYP3A7, ABCG2 NOTUM 828/4885RAB9A 1475/4885L3MBTL1 4553/4885
US-20130046001-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION BAX, NLN, CASP3 NOTUM 2486/4885RAB9A 2788/4885L3MBTL1 2556/4885
US-20150283243-A1 SOLID DISPERSIONS OF INSOLUBLE DRUG AND PREPARATION METHOD THEREOF SI, ABCG2, CYP3A7 NOTUM 930/4885RAB9A 1774/4885L3MBTL1 3702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.